Cytology, KRAS mutation analysis, and CEA (with a cut-off of 192 ng/mL) measurement did not reliably differentiate between MD-IPMN and CP in this pilot study. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.